ArticleFrontiers in cardiovascular medicine2025
An immunostaining-based approach for assessing myocardial viability in the infarcted mouse hearts.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal coronary flow rates for preservation of function during normothermic ex situ heart perfusion.The Journal of thoracic and cardiovascular surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With the growing need for reliable and precise detection of cell viability in spatial biology, we introduce an antibody-based staining of cardiac troponin I (cTnI) as a simple yet valuable tool for delineating cardiomyocyte viability in the early stages of myocardial infarction (MI). Methods & Results: In circulation, cTnI was found to be the most abundantly released biomarker within the first 24 h after MI. In heart sections, partial depletion of cTnI staining was observed within dying cardiomyocytes as early as 6 h, with almost absence by 24 h despite of preserved membrane integrity. In contrast, staining for other sarcomeric proteins, such as troponin T and Conclusion: These findings highlight the coordinated, stepwise breakdown of sarcomeric proteins following ischemic injury in the mouse heart and underscore the utility of antibody-based cTnI staining as a valuable tool for early myocardial viability assessment and infarct area detection with high spatial resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.